Over the last 10 years, electronic mail (email) has overtaken hard-copy as the primary communication tool. The regulatory guidance relating to clinical trials has for the most part not addressed email technology and the specific problems associated with its use. Consequently, the problems involved in managing trial-related emails are amongst the most common raised at meetings, conferences and internet discussion lists.
The GCP-RMA has identified the most common questions related to managing emails in clinical trials. On this web site, we have suggested practical answers to those questions.
If you have a question which is not published in this resource, please do not hesitate to contact the GCP-RMA and we shall endeavour to answer your query and publish it here.
Please note: Whilst the GCP-RMA takes every care in preparing answers to questions submitted and believes that all answers given are (1) compliant with prevailing regulations and legislation and (2) represent best practice, the Association accepts no liability for any consequences that may occur as a result of following any recommendations made.
